Last reviewed · How we verify
Intra-abdominal Lidocaine
At a glance
| Generic name | Intra-abdominal Lidocaine |
|---|---|
| Also known as | Xylocaine 5 mg/ml |
| Sponsor | Örebro University, Sweden |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Knee Osteoarthritis Disabling Pain Program for the Brazilian Unified Health System (NA)
- Effects Of Anaesthesia on Intraocular Pressure in Robotic Prostate Surgery (NA)
- Efficacy of Micro-fragmented Adipose Tissue Injection for Knee Osteoarthritis. (NA)
- Use of a Dual-agent Local Analgesic (Bupivacaine-meloxicam) for Abdominal Incisions in Patients Undergoing Retropubic Mid-urethral Sling Surgery (PHASE3)
- Effect of Addition of Dexmedetomidine or Ketamine to Intravenous Infusion of Lidocaine on Proinflammatory Cytokines in Pelvi-abdominal Cancer Surgeries. (PHASE1)
- The Effect of Continuous Intravenous Infusion of Lidocaine on PPCs and Prognosis in Emergency Surgical Patients With IAI (NA)
- Dexmedetomidine in Splanchnic Nerve Neurolysis (NA)
- Transverse Abdominis Plane Block Versus Ilioinguinal-iliohypogastric Block For Analgesia Following Hysterectomy (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Intra-abdominal Lidocaine CI brief — competitive landscape report
- Intra-abdominal Lidocaine updates RSS · CI watch RSS
- Örebro University, Sweden portfolio CI